Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
12:26pm, Wednesday, 24'th Dec 2025
Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio
12:14pm, Wednesday, 24'th Dec 2025
Sanofi (SNY) has announced an agreement to acquire Dynavax (DVAX) for $15.50 per share, valuing the deal at approximately $2.2 billion. This acquisition will en
Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio
11:24am, Wednesday, 24'th Dec 2025
Sanofi (SNY, Financials) stated on Wednesday that it would buy Dynavax Technologies for around $2.2 billion, or $15.50 per share in cash. This is a 39% premium
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
11:01am, Wednesday, 24'th Dec 2025
SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
Sanofi to acquire Dynavax in $2.2B Deal to boost adult vaccines
09:41am, Wednesday, 24'th Dec 2025
French pharmaceutical giant Sanofi SA said on Wednesday it has agreed to acquire US-based vaccines company Dynavax Technologies Corp in a $2.2 billion deal, strengthening its presence in the adult imm
This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.
07:59am, Wednesday, 24'th Dec 2025
Sanofi agrees to acquire Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.
Biggest Mover Wednesday: Dynavax Stock Soars on $2.2 billion Acquisition Deal
07:43am, Wednesday, 24'th Dec 2025
Shares of Dynavax Technologies (DVAX) surged about 37% on early Wednesday after French drugmaker Sanofi (SNY) agreed to buy the U.S. vaccine company in a cash d
Sanofi to acquire Dynavax for $2.2B, sending shares higher by 37%
06:49am, Wednesday, 24'th Dec 2025
Shares of Dynavax Technologies jumped sharply in premarket trading on Wednesday after the US vaccine maker agreed to be acquired by French pharmaceutical group Sanofi in an all-cash deal valued at abo
Sanofi To Buy Vaccine Maker Dynavax for $2.2 Billion
06:47am, Wednesday, 24'th Dec 2025
Sanofi will buy vaccine maker Dynavax Technologies for $2.2 billion, or $15.50 a share, adding to its adult immunizations. Dynavax stock soared.
Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy
06:21am, Wednesday, 24'th Dec 2025
Sanofi (SNY) to acquire Dynavax Technologies (DVAX) for $15.50 per share in cash, expanding its presence in adult immunization.
Sanofi to acquire US biotech Dynavax for $2.2 billion
03:08am, Wednesday, 24'th Dec 2025
French drugmaker Sanofi has entered into an agreement to acquire U.S. vaccines company Dynavax Technologies Corporation for around $2.2 billion (1.87 billion euros), it said on Wednesday.
Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal
01:49am, Wednesday, 24'th Dec 2025
The cash deal seeks to strengthen the French drugmaker's immunization portfolio after it suffered setbacks in clinical trials.
Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline
01:23am, Wednesday, 24'th Dec 2025
Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price on December 23, 2025 EMERYVILLE, Calif. , Dec. 24, 2025 /PRNewswire/ -- Sanofi announced today that it has
Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline
01:15am, Wednesday, 24'th Dec 2025
Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025. Sanofi announced today that it has entered into an agr
